Environmental risk assessment of selected pharmaceuticals in Turkey

Environmental Toxicology and Pharmacology

Volumn 38, Issue 1, 2014, Pages 79-83

  Oǧuz, Merve ^a   Mihçiokur, Hamdi ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Pharmaceuticals; Predicted environmental concentration; Predicted noeffective environmental concentration; Risk assessment

Indexed keywords

BENZALKONIUM; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; NAPROXEN; PARACETAMOL; ANTIINFECTIVE AGENT; CEFUROXIME; DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OCTANOL; SEWAGE; TOPICAL ANTIINFECTIVE AGENT; WATER; WATER POLLUTANT;

ACTIVATED SLUDGE; ADSORPTION; ARTICLE; BIOREMEDIATION; CONCENTRATION (PARAMETERS); ENVIRONMENTAL MONITORING; HAZARD ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TURKEY (REPUBLIC); WASTE WATER TREATMENT PLANT; ANALOGS AND DERIVATIVES; ANALYSIS; CHEMISTRY; SEWAGE; TURKEY; WATER POLLUTANT;

1-OCTANOL; ACETAMINOPHEN; ADSORPTION; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZALKONIUM COMPOUNDS; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ENVIRONMENTAL MONITORING; NAPROXEN; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; SEWAGE; TURKEY; WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84902335888     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2014.05.012     Document Type: Article

References (40)

1. Barnes K.K., Kolpin D.W., Furlong E.T., Zaugg S.D., Meyer M.T., Barber L.B. A national reconnaissance of pharmaceuticals and other organic wastewater contaminants in the United States Groundwater. Sci. Total Environ. 2008, 402:192-200.
2. Boxall A., Breton R. Pharmaceuticals and personal care products in the environment: regulatory drivers and research needs. QSAR and Combinational Science 2003, 22(3):399-409.
3. Buhner S.H. The Lost Language of Plants the Ecological Importance of Plant Medicines to Life on Earth 2002, Chelsea Green Publishing, Vermont.
4. Choi K., Kim Y., Park J., Park C.K., Kim M., Kim H.S., Kim P. Seasonal variations of several pharmaceutical residues in surface water and sewage treatment plants of HanRiver, Korea. Sci. Total Environ. 2008, 405:120-128.
5. DLEM (Department of Local Environmental Management), 2006. Initial assessment of eleven pharmaceuticals using the EMEA guideline in Norway.
6. Dobbs R.A., Wang L., Govind L. Sorption of toxic organic compounds on wastewater solids: correlation with fundamental properties. Environ. Sci. Technol. 1989, 23:1092-1097.
7. EC (European Commission) Assessment of potential risks to the environment posed by medicinal products for human use, excluding products containing live genetically modified organisms. EU Ad Hoc Working party, III/5504/94 Draft 4 1994.
8. EC (European Commission) Pharmaceuticals in the Environment: Current Knowledge and Need Assessment to Reduce Presence and Impact 2010, IWA Publishing.
9. EC (European Commission) Water Reclamation technologies for safe managed aquifer recharge 2012, IWA Publishing.
10. Francisco M., Soledad R., Dolores P.B. Solid-phase extraction of amphiphiles based on mixed hemimicelle/admicelle formation: application to the concentration of benzalkonium surfactants in sewage and river water. Anal. Chem. 2003, 75:6799-6806.
11. GACE (German Advisory Council on the Environment), 2007. Pharmaceuticals in the environment.
12. Gros M., Mozaz S.R., Barcelo D. Rapid analysis of multiclass antibiotic residues and some of their metabolites in hospital, urban wastewater and river water by ultra-high-performance liquid chromatography coupled to quadrupole-linear ion trap tandem mass spectrometry. J. Chromatogr. A 2013, 1292:173-188.
13. Grung M., Kallgvist T., Sakshaug S. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline. Ecotoxicol. Environ. Safety 2008, 71:328-340.
14. Halling-Sorensen B., Holten-Lützhoft H.C., Andersen H.R., Ingerslev F. Environmental risk assessment of antibiotic: comparison of mecillinam, trimethoprim and ciprofloxacin. J. Antimicrobial Chemotherapy 2000, 46:53-58.
15. Halling-Sorensen B., Nors Nielsen S., Lansky P.F., Ingerslev F., Holten Lutzhoft H.C., Jorgensen S.E. Occurrence, fate, and effects of pharmaceutical substances in the environment. Chemosphere 1998, 36(2):357-393.
16. Hartmann A., Alder A.C., Koller T., Widmer R.M. Identification of fluoroquinolone antibiotics as the main source of UmuC genotoxicity in native hospital wastewater. Environ. Toxicol. Chem. 1998, 17(3):377-382.
17. Hernando M.D., Heath E., Petrovic M., Barceló D. Trace-level determination of pharmaceuticals residues by LC-MS/MS in natural and treated waters. A pilot Survey Study. Anal. Bioanal. Chem. 2006, 385:985-991.
18. Hirsch R., Ternes T., Heberer K., Kratz K.L. Occurrence of antibiotics in the aquatic environment. Sci. Total Environ. 1999, 225(1-2):109-118.
19. Jones O.A.H., Voulvoulis N., Lester J.N. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 2002, 36:5013-5022.
20. Jones O.A.H., Voulvoulis N., Lester J.N. The occurrence and removal of selected pharmaceutical compounds in a sewage treatment works utilizing activated sludge treatment. Environ. Pollut. 2007, 145:738-744.
21. Latrou I.E., Stasinakis S.A., Thomaidis S.N. Estimation of potential environmental risks associated with human antibiotic consumption in two regions of Greece. Proceedings of the 12th International Conference on Environmental Science and Technology 2011, B-397-403.
22. Lee H.B., Peart T.E., Svoboda M.L. Determination of endocrine-disrupting phenols, acidic pharmaceuticals, and personal-care products in sewage by solid phase extraction and gas chromatography-mass spectrometry. J. Chromatogr. A 2005, 1094:122-129.
23. Lee H.B., Peart T.E., Svoboda M.L. Determination of Ofloxacin, Norfloxacin, and Ciprofloxacin in sewage by selective solid phase extraction liquid chromatography with fluorescence detection, and liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2007, 1139:45-52.
24. Lin A.Y.C., Tsai Y.T. Occurrence of pharmaceuticals in Taiwan's surface waters: impact of waste streams from hospitals and pharmaceutical product ion facilities. Sci. Total Environ. 2003, 407:3793-3802.
25. Kummerer K., Steger-Hartmann T., Meyer M. Biodegradability of the antitumor agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res. 1997, 3(11):2705-2710.
26. Kummerer K., Al-Ahmad A., Mersch-Sundermann V. Biodegradability of some antibiotics, elimination of the genotoxicity and affection of wastewater bacteria in a simple test. Chemosphere 2000, 40:701-710.
27. Kummerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources. Chemosphere 2001, 45(6-7):957-969.
28. Kummerer K. Pharmaceuticals in the Environment: Sources, Fate Effects and Risks 2004, Springer-Verlag, Berlin Heidelberg.
29. Morrison H.A. Bioconcentration and biomagnification in the aquatic environment. Environ. Health Sci. 2000, 189-231.
30. Remtsma T., Jekel M. Organic pollutants in the water cycle: properties, occurrence, analysis and environmental relevance of polar compounds 2006, Water Chemical Society, Weinheim.
31. Sebastine I.M., Wakeman R.J. consumption and environmental hazards of pharmaceutical substances in the UK. Trans I Chem E 2003, 81(B):229-235.
32. Stockholm County Council (2012) Environmentally classified pharmaceuticals report.
33. Stuer-Lauridsen F., Birkved M., Hansen L.P., Holten-Lutzhoft H.C., Halling-Sorensen B. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 2000, 40(7):783-793.
34. Stumpf M., Ternes T.A., Wilken R.D., Rodrigues S.V., Baumann W. Polar drug residue in sewage and natural waters in the State of Rio de Janeiro, Brazil. Sci. Total Environ. 1999, 225:135-141.
35. TSIa (Turkish Statistical Institutea), 2013. http://www.tuik.gov.tr/PreHaberBultenleri.do%3Fid=13425.
36. TSIb (Turkish Statistical Instituteb), 2013. http://tuikapp.tuik.gov.tr/cevredagitimapp/belediyeatiksu.zul.
37. T.S.P.O.(Turkey State Planning Organization) Drug industry specialization commission report ninth development plan (2007-2013). Ankara 2006.
38. Turkdogan İ.F., Yetilmezsoy K. Appraisal of potential environmental risks associated with human antibiotic consumption in Turkey. J. Hazard. Mater. 2009, 166:297-308.
39. US EPA (US Environmental Protection Agency) Estimation Program Interface EPI; Suite, version 3.10 2001, Environmental Protection Agency, Office of Pollution Prevention and Toxic's, Washington DC USA.
40. Webb S.F. Risk assessment approaches for pharmaceuticals. Proceedings of the International Seminar on Pharmaceuticals in the Environment 2000.